Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47,788 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: hu y. J Hematol Oncol. 2023 Feb 20;16(1):13. doi: 10.1186/s13045-023-01414-8. J Hematol Oncol. 2023. PMID: 36803531 Free PMC article. Clinical Trial. No abstract available.
[Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China.].
Wang JX, Huang XJ, Wu DP, Hu JD, Liu T, Hu Y, Meng FY, Chen XQ, Hou M, Li Y, Wang SJ, Wang JM, Ren HY, Yu L, Chen FY, Qiu LG, Jiang B, Sun AN, Liu TB, Zhu HL, Guo T, Xu D, Ji CY, Lü XY, Jiao L, Song XM, Huang HH. Wang JX, et al. Among authors: hu jd, hu y. Zhonghua Xue Ye Xue Za Zhi. 2009 Nov;30(11):721-5. Zhonghua Xue Ye Xue Za Zhi. 2009. PMID: 20137304 Review. Chinese.
Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, Chen BA, Fang MY, Feng JF, Fu WL, Guo HY, Hou M, Hou J, Hu Y, Hu XT, Hu XM, Huang LQ, Jin J, Li JY, Li J, Li W, Liang YM, Liu T, Liu QF, Liu YH, Mao P, Ouyang J, Qiu LG, Qiu L, Shao CK, Shi B, Song YP, Sun ZM, Wang QS, Wang C, Wang JM, Wang YS, Wang Z, Wu JB, Wu YX, Xia RX, Xue YQ, Yang BZ, Yang G, Yang ZL, Yu L, Yuan Z, Zhang S, Zhang Y, Zhao HG, Zhao L, Zhou DB, Zou SH, Zhu YF. Lai YY, et al. Among authors: hu xt, hu y, hu xm. Chin Med J (Engl). 2012 Aug;125(15):2663-70. Chin Med J (Engl). 2012. PMID: 22931972
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X. Wang J, et al. Among authors: hu j, hu y. Blood. 2015 Apr 30;125(18):2771-8. doi: 10.1182/blood-2014-09-601674. Epub 2015 Mar 12. Blood. 2015. PMID: 25766724 Free PMC article. Clinical Trial.
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Fang J, Zhang R, Wang H, Hong M, Wu Q, Nie D, You Y, Zhong Z, Li W, Hu Y, Xia L. Fang J, et al. Among authors: hu y. Leuk Res. 2016 Jul;46:61-8. doi: 10.1016/j.leukres.2016.04.014. Epub 2016 Apr 19. Leuk Res. 2016. PMID: 27131062
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
Zhu J, Huang H, Chen H, Zhang X, Li Z, Wu D, Zhou D, Song Y, Hu Y, Liang Y, Ren H, Huang H, Li N, Chen H, Hu J, Li J, Meng R, Wu J, Yu D, Huang X. Zhu J, et al. Among authors: hu j, hu y. Transfusion. 2018 Jan;58(1):81-87. doi: 10.1111/trf.14426. Epub 2017 Dec 13. Transfusion. 2018. PMID: 29238988 Clinical Trial.
Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Du X, Lai YY, Xiao Z, Liu T, Hu Y, Sun A, Li X, Shen ZX, Jin J, Yu L, Laille E, Dong Q, Songer S, Beach CL. Du X, et al. Among authors: hu y. Asia Pac J Clin Oncol. 2018 Jun;14(3):270-278. doi: 10.1111/ajco.12835. Epub 2017 Dec 28. Asia Pac J Clin Oncol. 2018. PMID: 29282890 Clinical Trial.
47,788 results
You have reached the last available page of results. Please see the User Guide for more information.